Syngene

Putting Science to Work

Next-Gen Modalities, Expertly Enabled

Syngene's integrated capabilities in Oligonucleotides, Peptides, & Conjugates. From discovery to GMP, we partner with you to accelerate novel modalities.

Our Novel Modalities Capabilities

Oligonucleotides	Peptides	Conjugates	Analytics
DNA/RNA (ASO, siRNA, miRNA, modified and unmodified) from design to GMP	Linear, cyclic, modified, labeled, and conjugated peptides - rapid prototype to scale	PDC, ODC, AOC, ADCs, Acid-amine coupling, Click Chemistry, Thiol-maleimide, S-S & C-S bond, GalNAc	Full characterization platform for oligos and peptides to de-risk and speed filings

How You Benefit?

End-to-end support	One partner from design ⟶ development ⟶ GMP
Scalable Platforms	Flexible synthesis from lab to commercial scale
Analytical Expertise	ICH-compliant method development and validation
Supply Chain Resilience	Diversified sourcing and alternate supplier strategy
Program Governance	Dedicated PM, transparent communication, risk management

Peptides

- Custom synthesis non-GMP and cGMP
- Scale: mg to kg, discovery up to commercialization
  Top of the art large scale solid phase synthesizer
- Natural, unnatural, modified AA, All D amino acid
- Linear, Branched, PEGylated, Lipidated, Disulfide bridged,
- Cyclic (head to tail, Lactam bridged, Stapled)
- Fluorescent, Label, Chelated (DOTA, AAZTA)
- Hydrophilic & Hydrophobic
- Library Synthesis up to 18 mer
- Ongoing expansion up to 1000L ready by end of 2026
- Advanced purification and full analytical characterization
- Assay integration for binding, stability, and cell penetration studies

Oligonucleotides

- Custom synthesis non-GMP and cGMP
- Scale discovery up to commercialization
  - Discovery 50 nmol to 200 umol
  - Development 0.25 to 4 mmol
  - Manufacturing Max of 40 mmol
  - Expansion to 400 mmol
- Natural DNA/RNA: over 100 mer
- ASO, siRNA, CpG, Aptamer, PMO, PNA
- Phosphodiester (PO), Phosphorothioate PS), Phosphorodithioate (PS2), Phosphoryl guanidine(PN)
- 2'Ome, 2'MOE, 2'Fluoro, Locked Nucleic acids (LNA)
- Method development, impurity profiling, stability studies, and release testing
- GMP manufacturing with robust documentation for IND/IMPD submissions

Conjugates

- Acid-amine coupling (peptides and protein, lipids, drugs, fluorophores)
- Alkyne-azide coupling (Click Chemistry)
- Thiol-maleimide coupling
- S-S and C-S bond formation
- Antibody oligo conjugation (AOC)
- GalNAc



Syngene
Putting Science to Work



Analytical Platforms

- Standard and specialized analytics for routine non-GMP/ cGMP release
- Dedicated facility for structural analysis, physicochemical characterization
- Analytical Method Development & Validation
- Impurity profiling, Sequencing, Characterization, Identification
- HRMS and MS/MS for sequence confirmation and variants
- LC/LC MS, GC MS, IC; elemental impurities per ICH Q3D
- Sterility/bioburden and endotoxin tests for injectables
- Forced degradation and stability indicating methods (ICH Q1A)
- Documentation of methods, CoA, and Regulatory reporting

Why it matters to you

- High purity material with tight impurity control
- Scale flexibility from early research to clinical supply
- Faster path to clinic with a single vendor model
- Rapid prototype generation and optimization
- Analytically defined material ready for downstream studies
- Integrated scale up supported by process and quality teams
- Accelerated timelines for Integrated clinical DS & DP

What You Gain?

Robust specs, clean CoAs, and audit-ready documentation that de-risks IND/IMPD filing and smooths scale-up.

Why Partner with Syngene?

- 30+ years of experience supporting end to end program
- Fully integrated CDMO model ensuring technical, regulatory, and environmental alignment (USFDA, PMDA, ISO)
- Commitment to advancing clients' pipelines and their sustainability agendas
- Manufacturing is strategically located across two sites – Bangalore & Mangalore, enabling scalability and business continuity
- Central support functions: unique PoC project manager, strategic sourcing
- Silver rating in the Ecovadis assessment
- Constant improvement of Environment, Social and Governance performance
- Zero liquid discharge facilities

Capacity & Scale

- Scale-up / scale-down models to meet regulatory needs and ensure process robustness
- Peptides: current GMP capacity ~250 mmol; roadmap to ~2000 mmol
- Oligonucleotides: expanding GMP capacity from ~45 mmol to ~400 mmol

How We Work with You

- Clear project plans and milestones with frequent scientific check-ins
- Integrated teams reduce handoffs and accelerate timelines
- Flexible tech-transfer and scaling to match program needs

At Syngene we put science to work

Let us accelerate your TIDES program — from idea to market.

Contact

bd@syngeneintl.com | www.syngeneintl.com

Syngene

Putting Science to Work

Scan the QR code to learn more

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

Syngene's 5500+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb, as well as 2.2 million sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

Stay Connected